Nasdaq:US$38.93 (+1.39) | HKEX:HK$60.10 (+0.40) | AIM:£5.56 (+0.14)
About Us

HUTCHMED is  an innovative, commercial-stage biopharmaceutical company committed to the discovery and global development of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.

We are among the first global-focused novel drug discovery companies in China. Over the past two decades, we have established a fully integrated R&D platform with world-class discovery and development capability. As of 2020, we have an in-house scientific team of around 680 professionals, and a pipeline of 11 clinical stage drug candidates in clinical studies around the world. Our first three oncology drugs are now approved and marketed in China - ELUNATE® (fruquintinib capsules), SULANDA® (surufatinib capsules) and ORPATHYS® (savolitinib tablets) .

We have also developed a profitable commercial platform with deep pan-China market access, which manufactures, markets and distributes our novel oncology products, as well as prescription drugs and consumer health products in China. We are expanding the geographic scope of our commercial operations to include the U.S. and Europe.

HUTCHMED is listed on the Nasdaq Global Select Market, the Stock Exchange of Hong Kong Limited and  the London Stock Exchange’s AIM market (Nasdaq/AIM : HCM ; HKEX : 13).

2000
FOUNDED
HCM
NASDAQ &
LONDON AIM
13
HKEX
11
IN-HOUSE DISCOVERED
CLINICAL STAGE DRUG CANDIDATES
3
APPROVED & MARKETED
PRODUCTS IN CHINA
1
NDA SUBMITTED IN THE US &
MAA SUBMITTED TO THE EMA
~40
CLINICAL TRIALS
AROUND THE GLOBE
1,400
DEDICATED SCIENTIFIC AND
COMMERCIAL PERSONNEL